Trial Profile

Rescue by radiotherapy and anti-CTLA4/PD-1 after failure of anti-PD-1 therapy in metastatic NSCLC patients, a proof-of-concept study.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 20 Oct 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
Indications Non-small cell lung cancer
Focus Adverse reactions; Proof of concept; Therapeutic Use
Acronyms RECLAIM

Most Recent Events

20 Oct 2023 Status changed from recruiting to completed.
13 Sep 2022 Results assessing safety and efficacy of combination of ipilimumab, nivolumab and medium dose radiotherapy in non-small cell lung cancer, presented at the 47th European Society for Medical Oncology Congress.
23 Aug 2021 New source identified and integrated (Netherlands Trial Register;NL8857)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com